Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
You may also be interested in...
FTC Rushes Patent Settlement Report In Push For Super Committee Action On "Pay-For-Delay"
The Federal Trade Commission rushed to press the data about the number of patent settlements between brand and generic companies in FY 2011 in an apparent effort to grab the attention of the Joint Select Committee on Deficit Reduction.
FTC Rushes Patent Settlement Report In Push For Super Committee Action On "Pay-For-Delay"
The Federal Trade Commission rushed to press the data about the number of patent settlements between brand and generic companies in FY 2011 in an apparent effort to grab the attention of the Joint Select Committee on Deficit Reduction.
Authorized Generics Do Not Deter Patent Challenges, FTC Says, But May Be Used To Delay Competition
Authorized generics modestly reduce drug prices during the first 180 days of generic competition and substantially undercut the revenues of competing generic firms, according to the Federal Trade Commission.